JP7239179B2 - Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物 - Google Patents

Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物 Download PDF

Info

Publication number
JP7239179B2
JP7239179B2 JP2019518292A JP2019518292A JP7239179B2 JP 7239179 B2 JP7239179 B2 JP 7239179B2 JP 2019518292 A JP2019518292 A JP 2019518292A JP 2019518292 A JP2019518292 A JP 2019518292A JP 7239179 B2 JP7239179 B2 JP 7239179B2
Authority
JP
Japan
Prior art keywords
cells
particles
exosomes
combination
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534258A5 (enrdf_load_stackoverflow
JP2019534258A (ja
Inventor
ジェイ． コピク，アリシャ
ワイ． イガラシ，ロバート
ジェイ． オイヤー，ジェレミア
エー． アルトメア，デボラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Central Florida Research Foundation Inc
Original Assignee
University of Central Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Central Florida Research Foundation Inc filed Critical University of Central Florida Research Foundation Inc
Publication of JP2019534258A publication Critical patent/JP2019534258A/ja
Publication of JP2019534258A5 publication Critical patent/JP2019534258A5/ja
Priority to JP2023025895A priority Critical patent/JP2023078140A/ja
Application granted granted Critical
Publication of JP7239179B2 publication Critical patent/JP7239179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019518292A 2016-10-05 2017-10-05 Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物 Active JP7239179B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023025895A JP2023078140A (ja) 2016-10-05 2023-02-22 Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404520P 2016-10-05 2016-10-05
US62/404,520 2016-10-05
PCT/US2017/055352 WO2018067825A1 (en) 2016-10-05 2017-10-05 Methods and compositions related to nk cell and anti-pdl1 cancer therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023025895A Division JP2023078140A (ja) 2016-10-05 2023-02-22 Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物

Publications (3)

Publication Number Publication Date
JP2019534258A JP2019534258A (ja) 2019-11-28
JP2019534258A5 JP2019534258A5 (enrdf_load_stackoverflow) 2021-05-20
JP7239179B2 true JP7239179B2 (ja) 2023-03-14

Family

ID=61831979

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019518292A Active JP7239179B2 (ja) 2016-10-05 2017-10-05 Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物
JP2023025895A Pending JP2023078140A (ja) 2016-10-05 2023-02-22 Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023025895A Pending JP2023078140A (ja) 2016-10-05 2023-02-22 Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物

Country Status (11)

Country Link
US (2) US20190309070A1 (enrdf_load_stackoverflow)
EP (1) EP3523416B1 (enrdf_load_stackoverflow)
JP (2) JP7239179B2 (enrdf_load_stackoverflow)
KR (2) KR102650803B1 (enrdf_load_stackoverflow)
CN (2) CN118453850A (enrdf_load_stackoverflow)
AU (2) AU2017340633B2 (enrdf_load_stackoverflow)
CA (1) CA3039532A1 (enrdf_load_stackoverflow)
DK (1) DK3523416T3 (enrdf_load_stackoverflow)
ES (1) ES3014658T3 (enrdf_load_stackoverflow)
SG (1) SG11201903032SA (enrdf_load_stackoverflow)
WO (1) WO2018067825A1 (enrdf_load_stackoverflow)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102373502B1 (ko) 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
CA3098471C (en) * 2018-05-22 2023-04-18 Nantkwest, Inc. Optimization of nk-92 cell growth using poloxamer
CN109939127A (zh) * 2018-06-13 2019-06-28 阿思科力(苏州)生物科技有限公司 Nk细胞的应用及包括该nk细胞的药物组合物及其应用
CN113365663A (zh) 2018-08-30 2021-09-07 Hcw生物科技公司 单链嵌合多肽和其用途
EP4592314A2 (en) * 2018-08-30 2025-07-30 ImmunityBio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
EP3844181A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3118943A1 (en) * 2018-11-15 2020-05-22 Torque Therapeutics, Inc. Methods and compositions for cancer immunotherapy
CN109652504B (zh) * 2018-12-27 2021-03-16 杭州迪相实业有限公司 一种同时检测外泌体膜蛋白和mRNA的方法
CN110205296B (zh) * 2019-01-29 2021-08-24 上海鑫湾生物科技有限公司 具有Fc突变体的抗体与效应细胞的组合、用途和制法
WO2021163298A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
IL295077A (en) 2020-02-11 2022-09-01 Hcw Biologics Inc Methods of treating age-related and inflammatory diseases
AU2021219720A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Chromatography resin and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
JP2023024168A (ja) * 2021-08-06 2023-02-16 国立大学法人 長崎大学 がんの治療剤
WO2023247324A1 (en) * 2022-06-24 2023-12-28 Cytovac A/S Novel combination treatment with adoptive cellular therapy
WO2024108058A2 (en) * 2022-11-18 2024-05-23 Nkmax Co., Ltd. Methods of inducing pd-l1 expression
WO2025010297A1 (en) * 2023-07-05 2025-01-09 Immunitybio, Inc. Ex vivo generation of immune effector cells from apheresis material intermediates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150359853A1 (en) 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enrdf_load_stackoverflow) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
CN104470535A (zh) * 2012-03-29 2015-03-25 阿尔托生物科学有限公司 用于治疗肿瘤的方法
LT3578201T (lt) * 2012-06-28 2023-05-25 University Of Central Florida Research Foundation Incorporated Nk ląstelių metodai ir kompozicijos
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
AU2014346852A1 (en) * 2013-11-05 2016-06-16 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
JP7049830B2 (ja) * 2014-10-27 2022-04-07 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ナチュラルキラー細胞のための方法及び組成物
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
WO2016134284A1 (en) 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
KR20170135860A (ko) * 2015-03-13 2017-12-08 싸이톰스 테라퓨틱스, 인크. 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150359853A1 (en) 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells，Cancer Immunology Research，2015年，Vol. 3, No. 10，p. 1148-1157
Interleukin-18 (IL-18)によるNatural Killer (NK)細胞活性化および腫瘍細胞のアポトーシス誘導，頭頸部腫瘍，Vol. 29, No. 1，2003年，p. 217-223
Interleukin-21 Increases Direct Cytotoxicity and IFN-γ Production of Ex Vivo Expanded NK Cells towards Breast Cancer Cells，Anticancer Research，2012年，Vol. 32，p. 839-846
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells，PLOS ONE，2012年，Vol. 7, No. 1，e30264
Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment，Cytotherapy，Vol. 18, No. 5，p. 653-663，doi: 10.1016/j.jcyt.2016.02.006.

Also Published As

Publication number Publication date
CN109952369B (zh) 2024-03-22
KR20190066035A (ko) 2019-06-12
EP3523416B1 (en) 2025-02-19
DK3523416T3 (da) 2025-03-03
EP3523416A1 (en) 2019-08-14
SG11201903032SA (en) 2019-05-30
US20190309070A1 (en) 2019-10-10
AU2017340633A1 (en) 2019-05-23
KR20240042177A (ko) 2024-04-01
EP3523416A4 (en) 2020-04-15
AU2024202350A1 (en) 2024-05-02
CN109952369A (zh) 2019-06-28
US20250136698A1 (en) 2025-05-01
JP2019534258A (ja) 2019-11-28
CA3039532A1 (en) 2018-04-12
ES3014658T3 (en) 2025-04-23
WO2018067825A1 (en) 2018-04-12
AU2017340633B2 (en) 2024-01-11
JP2023078140A (ja) 2023-06-06
KR102650803B1 (ko) 2024-03-25
CN118453850A (zh) 2024-08-09

Similar Documents

Publication Publication Date Title
JP7239179B2 (ja) Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物
CN113543799B (zh) 靶向dll3的嵌合抗原受体和结合剂
CN113784983B (zh) Cd93特异性治疗性抗原结合蛋白及其使用方法
TWI862870B (zh) 嵌合抗原受體療法t細胞擴增動力學及其用途
TW202328202A (zh) 記憶性ｎｋ細胞及抗癌雙特異性分子的組合癌症療法
KR20240012413A (ko) 폐암 치료를 위한 조성물 및 방법
TWI882495B (zh) 用於將免疫療法最佳化之因素
Brossart et al. OPEN ACCESS EDITED AND REVIEWED BY
TW202530421A (zh) 用於將免疫療法最佳化之因素
HK40046063A (en) Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
HK40063038A (en) Dll3 targeting chimeric antigen receptors and binding agents
IL311901A (en) Multiple specific binding agents against PD-L1 and CD137 in combination therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230222

R150 Certificate of patent or registration of utility model

Ref document number: 7239179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150